Free Trial
NASDAQ:MCRB

Seres Therapeutics (MCRB) Stock Price, News & Analysis

Seres Therapeutics logo
$18.80 -0.08 (-0.42%)
As of 11:25 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Seres Therapeutics Stock (NASDAQ:MCRB)

Key Stats

Today's Range
$18.50
$19.12
50-Day Range
$7.40
$19.44
52-Week Range
$6.53
$26.40
Volume
21,937 shs
Average Volume
99,484 shs
Market Capitalization
$164.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$73.67
Consensus Rating
Reduce

Company Overview

Seres Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

MCRB MarketRank™: 

Seres Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 340th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Seres Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on 1 buy rating, 1 hold rating, and 2 sell ratings.

  • Amount of Analyst Coverage

    Seres Therapeutics has received no research coverage in the past 90 days.

  • Read more about Seres Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Seres Therapeutics are expected to decrease in the coming year, from ($0.38) to ($0.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Seres Therapeutics is -4.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Seres Therapeutics is -4.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Seres Therapeutics has a P/B Ratio of 5.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Seres Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    15.50% of the float of Seres Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Seres Therapeutics has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Seres Therapeutics has recently increased by 16.13%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Seres Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Seres Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.50% of the float of Seres Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Seres Therapeutics has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Seres Therapeutics has recently increased by 16.13%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Seres Therapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Seres Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 6 people have searched for MCRB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Seres Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.70% of the stock of Seres Therapeutics is held by insiders.

  • Percentage Held by Institutions

    59.34% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Seres Therapeutics' insider trading history.
Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MCRB Stock News Headlines

A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
Seres Therapeutics’ Earnings Call: Progress Amid Challenges
Seres Therapeutics Reports Q2 Results and Leadership Change
Seres (MCRB) Q2 Loss Narrows 34%
See More Headlines

MCRB Stock Analysis - Frequently Asked Questions

Seres Therapeutics' stock was trading at $16.62 at the start of the year. Since then, MCRB shares have increased by 13.6% and is now trading at $18.88.

Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its earnings results on Wednesday, August, 6th. The biotechnology company reported ($2.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.72) by $0.45.
Read the conference call transcript
.

Seres Therapeutics's stock reverse split on Tuesday, April 22nd 2025.The 1-20 reverse split was announced on Thursday, April 10th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Seres Therapeutics (MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Top institutional investors of Seres Therapeutics include Geode Capital Management LLC (1.05%), Marshall Wace LLP (1.04%), Vontobel Holding Ltd. (0.92%) and XTX Topco Ltd (0.26%). Insiders that own company stock include Eric D Shaff, Thomas Desrosier, Matthew R Henn, Teresa L Young, David S Ege, Paula Cloghessy and Moltke Lisa Von.
View institutional ownership trends
.

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Seres Therapeutics investors own include PayPal (PYPL), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Micron Technology (MU), QUALCOMM (QCOM) and NIO (NIO).

Company Calendar

Last Earnings
8/06/2025
Today
8/27/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MCRB
CIK
1609809
Fax
N/A
Employees
330
Year Founded
2010

Price Target and Rating

High Price Target
$200.00
Low Price Target
$6.00
Potential Upside/Downside
+290.2%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.60)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$140 thousand
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-350.16%
Return on Assets
-67.69%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.57
Quick Ratio
1.57

Sales & Book Value

Annual Sales
$126.32 million
Price / Sales
1.31
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.76 per share
Price / Book
5.02

Miscellaneous

Outstanding Shares
8,750,000
Free Float
8,344,000
Market Cap
$165.20 million
Optionable
Optionable
Beta
2.90

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:MCRB) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners